GlassScriptPhysician profile
Amanda Del Moore
NPI 1932463288
$3,862.97
in general payments reported to CMS, 2019-2025
44 companies · $823 in 2025
The $823 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $681 · 2022: $626 · 2023: $857 · 2024: $877 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $536.54 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $449.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $443.55 | 2023-2025 | |
| Abbvie INC. | $356.80 | 2022-2025 | |
| Noven Therapeutics, LLC | $260.72 | 2023-2025 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $184.34 | 2021-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.08 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $123.76 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $109.15 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.42 | 2021-2025 | Jardiance, Synjardy |
| Lundbeck LLC | $91.46 | 2023-2025 | Rexulti |
| Pfizer INC. | $84.10 | 2021-2023 | |
| Abbott Laboratories | $78.69 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $78.56 | 2021-2022 | |
| Glaxosmithkline, LLC. | $74.25 | 2021-2023 | Trelegy Ellipta |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.